Safety and Reactogenicity of GSK Biologicals' dTaP Vaccine (Boostrix) in Healthy Vietnamese Children
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2017
Price : $35 *
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 16 Jul 2016 Results published in the Vaccine
- 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Mar 2014 Planned End Date changed from 1 May 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.